aCML is most specifically associated with mutations in SETBP1 and ethanolamine kinase 1 (ETNK1), which typically are found in 23%–38% and 3%–9% of patients, respectively [3, 4, 41, 42, 43]. Here, ETNK1 is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.